Editas Reports Results for 14 Participants in its Phase 1/2 CRISPR/Cas9 Clinical Trial for LCA10 from Foundation Fighting Blindness

Foundation Fighting Blindness

Editas Reports Results for 14 Participants in its Phase 1/2 CRISPR/Cas9 Clinical Trial for LCA10

4 minutes Posted Nov 18, 2022 at 1:29 pm.

0:00

4:31

Share at current time

Show notes

The company is seeking a partner to move the LCA10 program forward